Abstract
The introduction of the everolimus as immunosuppressant in the liver transplantation has been shown to be safe and effective in the prophylaxis and preservation of the renal function. Prospective follow-up and chart analysis of liver transplant patients treated with everolimus was performed. Purpose: To highlight the importance of the pharmacist in transplantation centers. Method: Along the study, 93 patients were included, being 72 under active treatment. The successful treatment depends on the multidisciplinary follow-up, and it is extremely important the involvement of the patient, making him to become positive and an active part of the treatment. Results: The most frequent problems were: patients cutting the everolimus tablet, late SL after dose adjustment, lack of adhesion to the collection, and serum level collection out of time. Discussion: Upon the introduction of new drugs, it is required to observe possible adverse events further to ensure that the patient correctly follows the treatment. Conclusion: The presence of the pharmacist in the transplantation center allows the patient to get a reference to clarify doubts on the proper use of immunosuppressant.
Highlights
The introduction of the everolimus as immunosuppressant in the liver transplantation has been shown to be safe and effective in the prophylaxis and preservation of the renal function
The purpose of this study is to demonstrate the importance of the pharmacist in the multidisciplinary care, especially when new drugs are introduced
In periods of EVR shortage in the public network, patients were advised on the best dose adjustment, based on serum level (SL)
Summary
The introduction of the everolimus as immunosuppressant in the liver transplantation has been shown to be safe and effective in the prophylaxis and preservation of the renal function. Purpose: To highlight the importance of the pharmacist in transplantation centers. Conclusion: The presence of the pharmacist in the transplantation center allows the patient to get a reference to clarify doubts on the proper use of immunosuppressant. The updating of the immunosuppressive protocol upon introducing everolimus (EVR), an inhibitor of the mammalian target of rapamycin (mTOR) complex in liver transplantation (LTx), has been shown to be safe and effective in the prophylaxis of rejection and preservation of renal function.[1,2]. The purpose of this study is to demonstrate the importance of the pharmacist in the multidisciplinary care, especially when new drugs are introduced
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
